Serum lipids and lipoprotein disorders in cancer patients

Alexopoulos, Constantinos; Blatsios, B.; Avgerinos, Alec

doi:10.1002/1097-0142(19871215)60:12<3065::aid-cncr2820601234>3.0.co;2-q

Cited by 112 publications

(103 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Framingham study found no association between cholesterol levels and the incidence of any cancer among women (Williams et al, 1981). However, cholesterol and triglyceride levels were increased among Greek women with breast cancer relative to controls (Alexopoulos et al, 1987).The observed increase in risk of breast cancer related to hyperlipidaemia in our study was modest and could have arisen through unrecognized selection or information bias, unmeasured confounding, or by chance. It would therefore be inappropriate to conclude that statin treatment lowered the risk of breast cancer in our study, simply because women treated for hyperlipidaemia were at no greater risk than normolipemic women.…”

contrasting

confidence: 71%

See 1 more Smart Citation

Statin use, hyperlipidaemia, and the risk of breast cancer

et al. 2002

View full text Add to dashboard Cite

Hydroxymethyl glutaryl coenzyme A inhibitors ('statins') are carcinogenic in rodents and an increased incidence of breast cancer was reported among pravastatin users in one randomised trial. We conducted a case -control study in the General Practice Research Database to evaluate the risk of breast cancer among 50-to 79-year old women treated with statins for hyperlipidaemia. Case and control women were matched by age, general practice, duration of prescription history in the General Practice Research Database, and index date. Adjusting for history of benign breast disease, body mass index, and use of hormone replacement therapy, women currently treated with statins had an estimated relative risk for breast cancer of 1.0 (95% confidence interval 0.6 -1.6) compared to women without hyperlipidaemia. Untreated hyperlipidaemia was associated with an increased risk of breast cancer (estimated relative risk 1.6; 95% confidence interval 1.1 -2.5). The estimated relative risk among women currently receiving only non-statin lipid-lowering drugs was similar to that of women with untreated hyperlipidaemia (1.8; 95% confidence interval 0.9 -3.4). We found no evidence for an increasing trend in breast cancer risk with increasing duration of statin use (median duration 1.8 years, maximum 8.6 years). (Newman and Hulley, 1996). Clinical trials focused on cardiovascular mortality and morbidity have had limited ability to assess the human carcinogenic potential of statins due to relatively short follow-up. Among 13 trials reporting cancer incidence and deaths as outcomes, with an average follow-up time of 3.3 years, no evidence was found of an overall increased risk of cancer (relative risk (RR) 1.03, 95% confidence interval (CI) 0.90 -1.17) or cancer deaths (RR 0.95, 95% CI 0.74 -1.21) among statin users (Hebert et al, 1997). However, concern was raised by the only study that reported on breast cancer risk, with 12 cases among pravastatin users and only one case in a placebo group of similar size (P=0.002) (Sacks et al, 1996).We used the General Practice Research Database (GPRD), an automated data source containing drug prescription and other medical information on more than 3 million residents of the UK, to study the possible relation of breast cancer to statin use and hyperlipidaemia. MATERIALS AND METHODSWe conducted a matched case -control study on the risk of breast cancer in relation to use of statins, non-statin lipid-lowering agents, and untreated hyperlipidaemia among women aged 50 -79 diagnosed with breast cancer in 1992 -1998 in the UK General Practice Research Database (GPRD). General Practice Research Database (GPRD)The GPRD started in 1988 and has been used extensively for research studies; the subset of data we have used during the past decade is of consistently high quality. (Jick et al, 1991) Some 350 practices contributed to data used in this report. In a previous study our group found that diagnoses of cancer are validated in 95% of cases for whom further information is obtained from general practitioners (Jic...

show abstract

contrasting

confidence: 71%

Section: Discussionmentioning

confidence: 95%

Statin use, hyperlipidaemia, and the risk of breast cancer

et al. 2002

View full text Add to dashboard Cite

show abstract

“…The results of our sludy confirm the findings of earlier studies as reported by Bani et al (17), Aiexopoulos et al (18), Kumar et el (2), Ray et al (4) and Bahadur et al (5). I-Io~ever, only serum tdglyceddes levels in pa6e~s with 10mast ~ were found to be higher as reported by Knapp Hoyer & Engholm (22) observed no as=mdation between LDL~ and breast cancer dsk, whereas, Bahadur st el (5) noticed a higher level of LDL-cholesterol in patients with breast cancer ~ to ncm~ healthy control ~omerk However, the data of present study also indicated a significant increase in serum LDL~ level among breast cencer p~dents.…”

Section: Di$cu8810nsupporting

confidence: 92%

Serum lipids, lipoproteins and sex-hormone binding globulin in breast cancer

Ray

Naik

Bahadur

et al. 2001

Indian J Clin Biochem

View full text Add to dashboard Cite

Serum levels of various lipid pammetms, i.e., triglycaddes, total cholesterol, alpha lipoprotein or high density lipoprotein (HDL)-cholesterol and beta lipoprotoin or low density lipoprotein (LDL),cholestmol ware measured in a total of 138 histologically proven cases of breast cancer along with 146 control women. The mean levels of serum tdglycacides, total cholesterol and LDL-cholesterol ware found to be signmcantly higher in breast cancer cases as compared to controls. However, lower mean levels of serum HOL.cholestorol and sex-hormone binding glubulin (SHBG) were observed in breast cancer patients than the control subjects. The results indicats a probable relation between serum lipids and the activity of sex-hormones. Moreover, the study reflects an overall disturbance of lipid metabolism in the pathological process of breast cancer.KEY WORD8 : Serum lipids, related proteins and female breast canoer.

show abstract

“…4 Recently, several studies have provided a significant association between serum lipid profile and cancer of various sites. 7 Similarly, studies on oral cancer and OPMDs also have revealed changes in serum lipid profile. Most of them found a significant hypocholesterolemia and varied findings on serum lipoprotein levels.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Serum Lipids and Lipoproteins as Prognosticators in Leukoplakia

Ganavi

Patil

Rao

2014

The Journal of Contemporary Dental Practice

View full text Add to dashboard Cite

Background: Oral cancer is the 8th most common cancer worldwide. Squamous cell carcinomas constitute 94% of all oral malignancies and are often preceded by leukoplakia. Despite many adjunctive techniques to monitor transformation of leukoplakia to oral squamous cell carcinoma (OSCC), the mortality rate is on the rise.Incidentally, patients diagnosed with oral potentially malignant disorders (OPMDs) and oral cancers manifest with low choles-terol levels. Given a thought, hypolipidemia may be a useful adjunctive tool as it reflects the initial changes within the neo-plastic cells, thus giving a red alert in malignant transformation of leukoplakia at the earlier stage. Aim:To evaluate the feasibility of serum lipid profile as an adjunct early marker for malignant transformation of leukoplakia to OSCC. Objectives:To estimate the serum cholesterol, triglycerides and lipoprotein (HDL, LDL, VLDL) levels in patients with leukoplakia, OSCC and age matched healthy control group.To compare the serum cholesterol, triglycerides and lipoprotein levels between patients of leukoplakia, OSCC and age matched healthy control group. Materials and methods:The study group comprised of selected 30 individuals which included 10 each of histopathologically confirmed OSCC, leukoplakia and healthy controls. A written consent was taken from all of them, and a thorough case history was recorded and then venous blood was collected 12 hours post fasting and centrifuged. The serum cholesterol, triglycerides and HDL were estimated by enzymatic and colorimetric methods using commercially available kits -Roche/ Hitachi cobas systems. Chemistry assay QC procured from Bio-Rad was used as control. VLDL and LDL were derived from these values. Results were statistically analyzed using ANOVA and post hoc Tukey Test. Results Conclusion:Convenience, universal availability, patient compatibility and simplicity being the merits of serum lipid profile make it a feasible adjunctive prognosticator in leukoplakic patients.

show abstract

Serum lipids and lipoprotein disorders in cancer patients

Cited by 112 publications

References 15 publications

Statin use, hyperlipidaemia, and the risk of breast cancer

Statin use, hyperlipidaemia, and the risk of breast cancer

Serum lipids, lipoproteins and sex-hormone binding globulin in breast cancer

Evaluation of Serum Lipids and Lipoproteins as Prognosticators in Leukoplakia

Contact Info

Product

Resources

About